BEVACIREL 100 MG ING

About

Bevacizumab is a recombinant humanized monoclonal antibody that functions as a potent anti-angiogenic agent. Its primary mechanism involves specifically binding to and neutralizing vascular endothelial growth factor (VEGF), a critical protein responsible for stimulating angiogenesis, the process by which tumors develop new blood vessels to sustain their growth. By inhibiting VEGF, bevacizumab effectively cuts off the tumor's blood supply, thereby impeding its growth, survival, and metastatic potential. This targeted therapy is a cornerstone in the management of various advanced or metastatic cancers, including colorectal, non-small cell lung, renal cell, and ovarian cancers, often administered in conjunction with standard chemotherapy to maximize therapeutic outcomes and improve patient prognosis.

Uses

• Metastatic colorectal cancer
• Non-small cell lung cancer
• Metastatic renal cell carcinoma
• Epithelial ovarian, fallopian tube, or primary peritoneal cancer

Directions For Use

Administered intravenously by a healthcare professional, typically every 2-3 weeks.

Benefits

• Inhibits tumor angiogenesis
• Reduces tumor blood supply
• Enhances chemotherapy efficacy
• Prolongs progression-free survival
• Broad spectrum of cancer indications
• Potential for improved patient outcomes

Side Effects

• Hypertension
• Proteinuria
• Bleeding events
• Arterial thromboembolism
• Gastrointestinal perforation
• Impaired wound healing
• Fatigue
• Headache
• Nausea
• Diarrhea
• Neutropenia
• Infusion-related reactions

Safety Measures

• Alcohol - No specific interaction with alcohol, but general health advice applies.
• Pregnancy - Contraindicated during pregnancy due to potential for severe fetal harm; use effective contraception.
• Breastfeeding - Avoid breastfeeding during treatment and for a period after the last dose.
• Liver - Use with caution in patients with liver conditions; monitor liver function.
• Kidney - Monitor for proteinuria and renal function; dose adjustment may be needed in severe cases.
• Lung - Monitor for pulmonary hemorrhage, especially in lung cancer patients.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.